drugset / Trial / NCT04257032

A Study in Healthy Men to Test the Influence of BI 1323495 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood

NCT04257032

Phase 1 Completed 28 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The main objectives of this trial are to investigate the relative bioavailabilities of rosuvastatin (Reference 1, Part 1) and dabigatran (Reference 2, Part 2) given alone and together with BI 1323495 (Test 1, Test 2) following oral administration.

Timeline

Start
2020-02-13
Primary completion
2020-09-23
Completion
2020-09-23

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1323495 Unknown Oral
Subject Dabigatran etexilate Unknown Oral
Subject Rosuvastatin Small molecule Oral

Indications

No indication recorded.